Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CDC42 | P60953 | 1/20 | 0.61 |
| ▸ | RAC1 | P63000 | 1/20 | 0.61 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365195 | 0.98 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL30640494 | 0.98 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL487168 | 0.98 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL30986302 | 0.86 | ABCB11 (0.57) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL20398797 | 0.85 | ABCB11 (0.65) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL443528 | 0.84 | CYP2A6 (0.80) | ABCB11AKR1C3AKR1C2PTGS1CYP1A2 | |
| SCHEMBL29367032 | 0.84 | CYP2A6 (0.80) | ABCB11AKR1C3AKR1C2PTGS1CYP1A2 | |
| SCHEMBL8582858 | 0.84 | CYP1A2 (0.55) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL25627482 | 0.83 | CYP1A2 (0.57) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11015086 | 0.82 | ABCB11 (0.93) | ABCB11AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167081-A1 | 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167081-A1 | 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| EP-3582789-B1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | UNIV NANTES (FR) | 2022-06-22 | — | — | EP | disclosed |
| US-9394273-B2 | Therapeutic prostaglandin receptor agonists | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9346795-B2 | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150329518-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | ALLERGAN, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135318-A1 | SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | ABCB11 1384/4885AKR1C3 3421/4885AKR1C2 2620/4885 |
| US-20150329518-A1 | THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS | PTGIR, PTGDR, PTGFR | ABCB11 1665/4885AKR1C3 513/4885AKR1C2 674/4885 |
| US-20230167081-A1 | 5-AMINO-2-PIPERIDINON-3-YL-1-OXOISOINDOLINE DERIVATIVES FOR DEGRADATION OF IKZF2 DEGRADERS | IKZF1, IKZF3, IKZF2 | ABCB11 4782/4885AKR1C3 2907/4885AKR1C2 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.